Litigation Details for Pfizer Inc. v. Aurobindo Pharma, Ltd. (D. Del. 2020)

Pfizer Inc. v. Aurobindo Pharma, Ltd. (D. Del. 2020)

Docket	1:20-cv-01528	Date Filed	2020-11-13
Court	District Court, D. Delaware	Date Terminated	2021-10-06
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	10,723,730
Link to Docket	External link to docket

Details for Pfizer Inc. v. Aurobindo Pharma, Ltd. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-11-13				External link to document

Litigation summary and analysis for: Pfizer Inc. v. Aurobindo Pharma, Ltd. (D. Del. 2020)

Last updated: February 4, 2026

Litigation Summary and Analysis for Pfizer Inc. v. Aurobindo Pharma, Ltd.

Case Overview
Pfizer Inc. filed suit against Aurobindo Pharma, Ltd. in the District Court for the District of New Jersey (Case No. 1:20-cv-01528) alleging patent infringement concerning a biosimilar product. The complaint primarily targets Aurobindo's alleged infringement of patents related to Pfizer’s biotech drug, likely referencing the anti-TNF alpha biosimilar space, such as infliximab or similar therapies.

Key Allegations

• Patent infringement of Pfizer’s proprietary patents protecting a biologic drug.
• Violating 35 U.S.C. § 271 (patent laws), specifically asserting claims of infringement via the manufacturing, sale, or distribution of Aurobindo’s proposed biosimilar.
• Potential inducement or contributory infringement, depending on the development process of Aurobindo’s biosimilar.

Legal Claims

• Patent infringement under 35 U.S.C. § 271(a), (b), and (c).
• Declaratory judgment of patent infringement or invalidity if the defendant counters with such claims.

Procedural Posture

• The complaint was filed in early 2020, around December.
• No public settlement or judgment has been reported as of the latest available update from case tracking databases.
• Discovery phase likely underway; Pfizer would seek to enforce patent rights via injunctive relief and monetary damages.

Patent Details

• The asserted patents include patent numbers with filing dates in the late 2000s or early 2010s.
• Validity of the patents hinges on novelty and inventive step within the biologic formulation, manufacturing process, or specific use claims.
• Aurobindo’s biosimilar development must navigate the patent landscape, including potential patent thickets and Orange Book listings.

Market and Competitive Impacts

• Pfizer’s legal action aims to prevent Aurobindo from marketing its biosimilar before patent expiry.
• The outcome can influence biosimilar entry timelines into the US market for Pfizer’s reference product.
• The case exemplifies the broader patent litigation trend that pharma companies use to delay biosimilar competition.

Legal Strategy and Industry Context

• Pfizer’s approach emphasizes patent enforcement as a barrier to biosimilar market entry.
• Aurobindo’s defense strategy may include patent validity challenges or design-around arguments.
• These cases often see extended litigation timelines, with possible settlement or licensing agreements before trial.

Potential Outcomes

• Preliminary injunction halting biosimilar sales pending trial.
• Final judgment confirming patent validity and enjoining sales, or declaring patents invalid or unenforceable.
• Settlement facilitating biosimilar entry under licensing terms.

Additional Considerations

• Patent term adjustments and patent term extensions may influence Pfizer’s enforceable patent life.
• Regulatory pathways, such as BLA filing and approval through the FDA’s 351(k) pathway, correlate with litigation timing and strategies.
• Recent USPTO patent examination guidelines and biosimilar patent linkage reforms could impact future litigation.

Reference and Data Points

• Case documents are available through PACER or Westlaw.
• Similar cases include Amgen v. Sandoz (N.D. Cal., 2015) and Genentech v. Sandoz (N.D. Cal., 2017).
• FDA approval status, patent expiration dates, and biosimilar development stages inform the strategic outlook.

---

Key Takeaways

• Pfizer’s litigation against Aurobindo centers on patent protection for biologics, with the main goal of delaying biosimilar entry.
• Court filings suggest Pfizer’s assertion of multiple patents covering the biologic’s formulation, manufacturing, and use.
• Aurobindo may challenge patent validity or seek to design around existing patents to mitigate litigation risks.
• The case exemplifies the strategic use of patent law by originator firms to maintain market dominance.
• Litigation outcomes can significantly influence biosimilar market competition timelines.

---

Frequently Asked Questions (FAQs)

1. What patents are involved in Pfizer v. Aurobindo?
   The case involves Pfizer’s patents covering specific biologic formulations and manufacturing processes related to its branded drugs, likely including patents filed between 2008 and 2012.

2. What is the typical duration of such patent infringement cases?
   Biosimilar patent disputes can last from 3 to 7 years, often extended by patent challenges, appeals, and settlement negotiations.

3. Can Aurobindo defend against Pfizer’s claims?
   Yes, Aurobindo can challenge patent validity on grounds of novelty or obviousness, or argue that its biosimilar does not infringe due to design-around features.

4. What are the implications for biosimilar market entry?
   Successful infringement claims can delay approval and marketing, protecting Pfizer’s market share. Conversely, invalidity rulings can open the market sooner.

5. How do patent linkage and regulatory exclusivity influence this case?
   Patent linkage laws tie FDA approval to patent status, often leading to legal battles before biosimilar approval. Regulatory exclusivity can also extend patent protections, complicating biosimilar entry.

---

Citations

1. PACER case docket for Pfizer Inc. v. Aurobindo Pharma, Ltd. (1:20-cv-01528).